• This article is designed to help you think through whether Lantheus Holdings, at around US$103, is still offering value or if most of the opportunity is already priced in.
• The stock has shown strong recent price action, with returns of 9.7% over the past week, 22.1% over the past month, 53.1% year to date, and 39.5% over the past year.
• Recent coverage has focused on Lantheus as a specialist in medical imaging and diagnostics, with investors closely watching how its product portfolio positions the company within the broader healthcare sector. Headlines have generally framed the stock in the context of sector interest in imaging and radiopharmaceuticals rather than short term trading themes.
• Lantheus currently has a valuation score of 4 out of 6. This sets up a closer look at how different valuation methods line up for this stock and points to an even broader way to think about value that will be covered at the end of this article.

Approach 1: Lantheus Holdings Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a stock might be worth by projecting future cash flows and discounting them back to today using an appropriate rate. It is essentially asking what all those future dollars are worth in $ right now.

For Lantheus Holdings, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month Free Cash Flow is about $331.5 million. Analysts provide explicit forecasts for the next few years, and Simply Wall St then extrapolates further to build a ten year path, which includes projected Free Cash Flow of $559 million in 2030. Each of those yearly cash flows is discounted back to today to estimate what they might collectively be worth in present value terms.

On this basis, the DCF model suggests an intrinsic value of about $191.18 per share, using $ cash flow projections. Compared with the recent share price around $103, this implies the stock is 46.1% undervalued according to this methodology.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Lantheus Holdings is undervalued by 46.1%. Track this in your watchlist or portfolio, or discover 49 more high quality undervalued stocks.

Approach 2: Lantheus Holdings Price vs Earnings

For profitable companies, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It connects the share price directly to current earnings, which is usually a key driver of long term returns.

What counts as a “normal” P/E depends on how the market views a company’s growth potential and risk. Higher expected growth or lower perceived risk can support a higher P/E, while slower growth or higher risk usually lines up with a lower multiple.

Lantheus Holdings currently trades on a P/E of 24.03x. This sits close to the Medical Equipment industry average P/E of 24.53x and the peer average of 23.61x, so on simple comparisons the stock is roughly in line with similar companies.

Simply Wall St’s Fair Ratio concept goes a step further. It estimates what P/E might be reasonable for Lantheus Holdings after considering factors such as earnings growth, industry, profit margins, market cap and risk profile. Because it adjusts for these company specific factors, it can be more informative than relying only on peer or industry averages.

For Lantheus Holdings, the Fair Ratio is 26.32x, which is higher than the current 24.03x P/E. On this measure, the stock screens as undervalued.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Lantheus Holdings Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives are introduced here as simple stories you create about Lantheus Holdings that tie your view of its products, competition and risks to explicit forecasts for revenue, earnings and margins, and then to a fair value that can be compared with the current share price.

On Simply Wall St’s Community page, Narratives are available as an easy tool that lets you set out your assumptions, link them to a valuation, and see in one place whether your fair value suggests the stock is expensive or cheap relative to today’s price. This can help you decide if it is closer to a buy, a hold, or a sell for your own portfolio.

Narratives also update automatically when new data, news or earnings are added to the platform. You can see in real time how a change in Lantheus Holdings guidance, pricing trends in PSMA PET imaging, or progress in the Alzheimer’s portfolio flows through to future earnings estimates and your view of fair value.

For example, one investor’s Lantheus Holdings Narrative might look closer to the more optimistic forecast that earnings could reach about US$779.6m by 2029 with a fair value around US$114. Another might lean toward a more cautious view with earnings nearer US$286.6m and a fair value near US$76. Seeing these side by side makes it clear that different stories and assumptions lead to very different conclusions about value even for the same stock.

For Lantheus Holdings however we will make it really easy for you with previews of two leading Lantheus Holdings Narratives:

Fair value in this bullish narrative: US$104.08 per share.

At the last close of US$103.00, this narrative implies the stock is about 1% below its fair value.

Implied revenue growth used in this narrative: 7.37% per year.

• Assumes Alzheimer’s and prostate cancer imaging, plus several new launches, broaden the product base and support higher earnings over time.
• Builds in margin expansion helped by new PYLARIFY formulations and acquisitions, while still flagging risks around pricing, reimbursement and integration.
• Anchors on analyst consensus that points to earnings of US$431.2m by 2029 and a P/E of 17.3x, which together support a fair value close to US$104 per share.

Fair value in this bearish narrative: US$76.00 per share.

At the last close of US$103.00, this narrative suggests the stock is about 35% above its fair value.

Implied revenue growth used in this narrative: 3.73% per year.

• Frames Lantheus as heavily exposed to pricing pressure and reimbursement shifts in PSMA PET, with a lot resting on a small group of products.
• Assumes new launches and acquisitions take longer to contribute meaningfully, while costs and integration needs keep a lid on margin progress.
• Ties these assumptions to a fair value of US$76 per share, using more cautious growth, profitability and discount rate settings than the consensus case.

Whichever side sounds closer to your own view, using Narratives lets you adjust the numbers, stress test both cases and see how your fair value for Lantheus Holdings moves as you tweak growth, margins and the P/E you are willing to pay. See what the community is saying about Lantheus Holdings.

Do you think there's more to the story for Lantheus Holdings? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.